Cargando…

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez, Luis Javier, Lin, Leyi, Blaylock, Jason M., Lyons, Arthur G., Bauer, Kristen M., De La Barrera, Rafael, Simmons, Monika, Jarman, Richard G., Currier, Jeffrey R., Friberg, Heather, Danko, Janine R., Teneza-Mora, Nimfa C., Putnak, J. Robert, Eckels, Kenneth H., Thomas, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559679/ https://www.ncbi.nlm.nih.gov/pubmed/26149862 http://dx.doi.org/10.4269/ajtmh.14-0819

Ejemplares similares

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
por: Friberg, Heather, et al.
Publicado: (2020)

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial
por: Danko, Janine R., et al.
Publicado: (2018)

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States
por: Schmidt, Alexander C., et al.
Publicado: (2017)

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques
por: Fernandez, Stefan, et al.
Publicado: (2015)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
por: Friberg, Heather, et al.
Publicado: (2022)

Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine
por: Simmons, Monika, et al.
Publicado: (2016)

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico
por: Diaz, Clemente, et al.
Publicado: (2018)

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study
por: Diaz, Clemente, et al.
Publicado: (2020)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults
por: Thomas, Stephen J., et al.
Publicado: (2013)

Dengue Virus Exposures Among Deployed U.S. Military Personnel
por: Hesse, Elisabeth M., et al.
Publicado: (2017)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Diversity and Origin of Dengue Virus Serotypes 1, 2, and 3, Bhutan
por: Dorji, Tandin, et al.
Publicado: (2009)

Immunological Assays used to Support Efficacy of Zika Virus Vaccines
por: Eckels, Kenneth H., et al.
Publicado: (2019)

Identification of All Dengue Serotypes in Nepal
por: Malla, Sarala, et al.
Publicado: (2008)

Within-host viral dynamics of dengue serotype 1 infection
por: Clapham, Hannah E., et al.
Publicado: (2014)

Acute macular neuroretinopathy in dengue virus serotype 1
por: Guardiola, Gabriel A., et al.
Publicado: (2022)

Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial
por: Watanaveeradej, Veerachai, et al.
Publicado: (2014)

Nucleotide substitutions in dengue virus serotypes from Asian and American countries: insights into intracodon recombination and purifying selection
por: Behura, Susanta K, et al.
Publicado: (2013)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
por: Waickman, Adam T., et al.
Publicado: (2019)

Phage-Mediated Molecular Detection (PMMD): A Novel Rapid Method for Phage-Specific Bacterial Detection
por: Malagon, Francisco, et al.
Publicado: (2020)

Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2020)

Kinetics of Viremia and NS1 Antigenemia Are Shaped by Immune Status and Virus Serotype in Adults with Dengue
por: Tricou, Vianney, et al.
Publicado: (2011)

Immunological serotype interactions and their effect on the epidemiological pattern of dengue
por: Recker, Mario, et al.
Publicado: (2009)

Myanmar Dengue Outbreak Associated with Displacement of Serotypes 2, 3, and 4 by Dengue 1
por: Thu, Hlaing Myat, et al.
Publicado: (2004)

Comparative Study of Immunogenic Properties of Purified Capsular Polysaccharides from Streptococcus suis Serotypes 3, 7, 8, and 9: the Serotype 3 Polysaccharide Induces an Opsonizing IgG Response
por: Goyette-Desjardins, Guillaume, et al.
Publicado: (2020)

Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection
por: Friberg, Heather, et al.
Publicado: (2018)

Analysis and identification of genomic and immunogenic features of dengue serotype 3 genomes obtained during the 2019 outbreak in Bangladesh
por: Shirin, Tahmina, et al.
Publicado: (2022)

High performance dengue virus antigen-based serotyping-NS1-ELISA (plus): A simple alternative approach to identify dengue virus serotypes in acute dengue specimens
por: Prommool, Tanapan, et al.
Publicado: (2021)

Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells
por: Hunsawong, Taweewun, et al.
Publicado: (2015)

Circulation of Dengue Virus Serotype 1 Genotype V and Dengue Virus Serotype 2 Genotype III in Tocantins State, Northern Brazil, 2021–2022
por: de Souza, Ueric José Borges, et al.
Publicado: (2023)

Evidence of HLA-DQB1 Contribution to Susceptibility of Dengue Serotype 3 in Dengue Patients in Southern Brazil
por: Cardozo, Daniela Maria, et al.
Publicado: (2014)

Molecular Surveillance of Dengue in Semarang, Indonesia Revealed the Circulation of an Old Genotype of Dengue Virus Serotype-1
por: Fahri, Sukmal, et al.
Publicado: (2013)

Potential risk for dengue hemorrhagic fever: the isolation of serotype dengue-3 in Mexico.
por: Briseño-García, B, et al.
Publicado: (1996)

Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2021)

Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection
por: Auerswald, Heidi, et al.
Publicado: (2021)

Air Travel Is Associated with Intracontinental Spread of Dengue Virus Serotypes 1–3 in Brazil
por: Nunes, Marcio R. T., et al.
Publicado: (2014)

Dengue Virus Serotypes 1 and 2 Responsible for Major Dengue Outbreaks in Nepal: Clinical, Laboratory, and Epidemiological Features
por: Dumre, Shyam Prakash, et al.
Publicado: (2017)

Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody
por: Trirawatanapong, Thaweesak, et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_6cfbftgurknva80ov93prmgb01